Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00888446
Other study ID # IAVI A002
Secondary ID
Status Completed
Phase Phase 2
First received April 23, 2009
Last updated December 13, 2012
Start date October 2005
Est. completion date December 2007

Study information

Verified date December 2012
Source International AIDS Vaccine Initiative
Contact n/a
Is FDA regulated No
Health authority South Africa: Medicines Control CouncilUganda: National Council for Science and TechnologyZambia: Ministry of Health
Study type Interventional

Clinical Trial Summary

This phase 2 study will evaluate the safety, immunogenicity and optimal timing of two injections at three dose levels of the tgAAC09 vaccine in healthy volunteers. Study volunteers will receive two intramuscular injections of tgAAC09 or placebo at Months 0 and 6 (groups A, C, E and G) or at Months 0 and 12 (groups B, D and F) and be followed for a total of 18 months following the first injection with the exception of group G in which volunteers will be followed for 12 months after the first injection (6 months after the second injection). This study will explore whether boosting is possible, and compare a shorter and more practical six-month time interval with a twelve-month time interval.


Description:

The study design will also assess the effect of the presence of anti-AAV2 capsid neutralizing antibodies at the time of vaccination on the safety and immunogenicity of tgAAC09. Since the prevalence of pre-existing neutralizing antibodies to AAV2 capsid is high (IAVI and Targeted Genetics, data on file), this protocol amendment adds Group G which is composed of volunteers who have documented pre-existing anti-AAV2 capsid neutralizing antibodies titers ≤ 1/8. This will assure that there are sufficient numbers of volunteers with and without antibodies for a useful comparison.


Recruitment information / eligibility

Status Completed
Enrollment 91
Est. completion date December 2007
Est. primary completion date December 2007
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Healthy male or female

- Age at least 18 years on the day of screening and no greater than 50 years on the day of the first study injection

- Willing to comply with the requirements of the protocol and available for follow up for the planned duration of the study

- Able and willing to give informed consent.

- Willing to undergo HIV testing, counseling and receive results

- If sexually active female of child-bearing potential (not menopausal or anatomically sterile), willing to use an effective method of contraception (hormonal contraceptives; intrauterine contraceptive device (IUCD); condoms; anatomical sterility in self or partner) from screening until at least four months after last study injection and willing to undergo urine pregnancy tests at screening, prior to each injection and four months after the last injection

- If sexually active male, willing to use a method of contraception (such as condoms) from screening until four months after the last study injection

Exclusion Criteria:

- HIV-1 or HIV-2 infection

- Active tuberculosis

- Clinically relevant abnormality on history or examination including history of immunodeficiency, or cancer, or autoimmune disorder

- Use of systemic corticosteroids, immunosuppressive or anticancer medications in the last six months

- Chronic condition that, in the opinion of the investigator or the designated trial physician, would make the volunteer unsuitable for the study

- Any of the following abnormal laboratory parameters:

- Hemoglobin <9.0 g/dL (females), <12.0 g/dL (males)

- Absolute Neutrophil Count (ANC): = 999/mm3

- Absolute Lymphocyte Count (ALC): = 500/mm3

- Platelets: decreased = 90,000 or increased = 550,000/mm3

- Creatinine: > 1.4 x ULN

- AST: >3.0 x ULN

- ALT: >3.0 x ULN

- Urine dipstick: blood = 2+ or more (except in menstruating females); protein = 2+ or more

- Any of the following high-risk behaviors:

- Had unprotected vaginal or anal sex with a known HIV positive person in the past six months

- Had unprotected vaginal or anal sex with a casual partner (i.e. no continuing established relationship) in the past six months

- Engaged in sex work for money or drugs in the past six months

- Used injection drugs illegally in the past six months

- Acquired a sexually transmitted infection (STI) in the past six months

- If female, pregnant, lactating or planning a pregnancy within four months after last study injection

- Receipt of live attenuated vaccine within 30 days or other vaccine within 14 days of the first study injection

- Receipt of blood transfusion or blood products six months prior to the first study injection

- Participation in another clinical trial of an investigational product currently or within last 12 weeks of first study injection or expected participation during this study

- Prior receipt of an investigational HIV vaccine

- History of severe local or systemic reaction to vaccination(s) or history of severe allergic reactions

- History of major neurological or psychiatric disorders

- Positive for hepatitis B surface antigen, active untreated syphilis (confirmed by treponemal test such as TPHA in addition to nontreponemal test such as RPR) or other active sexually transmitted diseases

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
tgAAC09

tgAAC09

tgAAC09

Other:
Formulation buffer
Sterile isotonic buffered salt solution

Locations

Country Name City State
South Africa Desmond Tutu HIV Centre Cape Town Cape Town
South Africa Medunsa South Africa
South Africa Perinatal HIV Research Unit, Baragwanath Hospital Soweto
Uganda Uganda Virus Research Institute Entebbe
Zambia Zambia-Emory HIV Research Project (ZEHRP) Lusaka

Sponsors (2)

Lead Sponsor Collaborator
International AIDS Vaccine Initiative Targeted Genetics Corporation

Countries where clinical trial is conducted

South Africa,  Uganda,  Zambia, 

References & Publications (1)

Vardas E, Kaleebu P, Bekker LG, Hoosen A, Chomba E, Johnson PR, Anklesaria P, Birungi J, Barin B, Boaz M, Cox J, Lehrman J, Stevens G, Gilmour J, Tarragona T, Hayes P, Lowenbein S, Kizito E, Fast P, Heald AE, Schmidt C. A phase 2 study to evaluate the saf — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Safety: proportion of volunteers with severe local and systemic reactions, proportion of volunteers with other SAEs (including laboratory abnormalities) related to study vaccine, number of volunteers with SAEs related to study vaccine 18 months Yes
Primary Proportion of volunteers with HIV-1 specific T- cell responses quantified by ?-IFN ELISPOT and magnitude of the response, and proportion of volunteers with HIV-1 specific binding antibodies and magnitude of the response 18 months No
Secondary Safety: high versus low or negative titres of neutralizing antibodies to AAV2 at the time of each vaccination 18 months Yes
Secondary Immunogenicity: proportion of volunteers with HIV-1 specific T- cell responses by ?-IFN CFC or other T-cell assays 18 months No
Secondary Immunogenicity endpoints in volunteers with high versus low or negative titres of neutralizing antibodies to AAV2 at the time of each vaccination 18 months No
Secondary Immunogenicity endpoints in volunteers with versus without four-fold or greater increase in titres of neutralizing antibodies to AAV2 after vaccination 18 months No
Secondary Immunogenicity endpoints after the second study injection, compared with the first study injection 18 months No
Secondary Immunogenicity endpoints after the second study injection following a twelve-month interval compared to a six-month interval 18 months No
Secondary Vaccine biodistribution: presence and persistence of vaccine in peripheral blood mononuclear cells (PBMC), saliva, nasal swabs, urine and semen or cervical/vaginal secretions 18 months No
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2

External Links